SINGAPORE, Dec. 2, 2024 /PRNewswire/ — George Clinical, a leading global clinical research organisation, is pleased to announce the appointment of Tony Proctor, C.P.A., as Chief Financial Officer (CFO). With over 25 years of financial leadership experience, Tony brings a wealth of expertise in driving operational excellence, strategic planning, and transformational growth.
Tony Proctor, George Clinical, Chief Financial Officer
“I am honored to join George Clinical and contribute to its mission of improving health outcomes through innovative clinical research,” said Tony Proctor. “I look forward to partnering with the talented team to enhance financial operations and support the company’s global vision.”
Tony has held CFO and executive leadership roles at Lexitas, Parexel, and Syneos Health. He was a key architect of organic revenue acceleration initiatives at these organisations, implementing best-in-class financial disciplines, major organisational and systems upgrades, and transformative M&A processes. His leadership has consistently delivered measurable results, including driving strategic growth initiatives and optimising financial operations on a global scale.
“We are thrilled to welcome Tony to George Clinical at this exciting stage of our growth,” said Mary Gunn, CEO of George Clinical. “His extensive expertise in financial strategy and operational leadership will be instrumental in advancing our business and delivering exceptional value to customers across the globe.”
Tony holds an M.B.A. in Finance from Campbell University, a B.S. in Accounting, and a B.A. in Business/Finance from North Carolina State University. He is also a Certified Public Accountant (CPA) licensed in North Carolina.
About George Clinical
George Clinical is a leading global clinical research organisation headquartered in Singapore. Driven by scientific excellence and operational expertise, the company provides comprehensive clinical trial services to clients globally, offering solutions across all trial phases. For more information about George Clinical, visit www.georgeclinical.com.
Contact: Donna McDonnell, T +1 901 229 5345, [email protected]
ข่าวที่เกี่ยวข้อง
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
- 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
